An Rgd Sequence in the P2y2 Receptor Interacts with αVβ3 Integrins and Is Required for Go-Mediated Signal Transduction by Erb, Laurie et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/2001/04/491/11 $5.00
The Journal of Cell Biology, Volume 153, Number 3, April 30, 2001 491–501
http://www.jcb.org/cgi/content/full/153/3/491 491
 
An RGD Sequence in the P2Y
 
2
 
 Receptor Interacts with 
 
a
 
V
 
b
 
3
 
 Integrins and 
Is Required for G
 
o
 
-mediated Signal Transduction
 
Laurie Erb,* Jun Liu,* Jonathan Ockerhausen,
 
‡
 
 Qiongman Kong,* Richard C. Garrad,* Korey Grifﬁn,* 
 
Chris Neal,* Brent Krugh,* Laura I. Santiago-Pérez,
 
§
 
 Fernando A. González,
 
§
 
 Hattie D. Gresham,
 
i
 
John T. Turner,
 
‡
 
 and Gary A. Weisman*
 
*Department of Biochemistry and 
 
‡
 
Department of Pharmacology, University of Missouri-Columbia, Columbia, Missouri 65212; 
 
§
 
Department of Chemistry, University of Puerto Rico, Rio Piedras, Puerto Rico 00931; and 
 
i
 
Department of Molecular Genetics 
and Microbiology, University of New Mexico, Albuquerque, New Mexico 87131
 
Abstract. 
 
The P2Y
 
2
 
 nucleotide receptor (P2Y
 
2
 
R) con-
 
tains the integrin-binding domain arginine-glycine-
aspartic acid (RGD) in its ﬁrst extracellular loop, rais-
ing the possibility that this G protein–coupled receptor
interacts directly with an integrin. Binding of a peptide
corresponding to the ﬁrst extracellular loop of the
P2Y
 
2
 
R to K562 erythroleukemia cells was inhibited by
 
antibodies against 
 
a
 
V
 
b
 
3
 
/
 
b
 
5
 
 integrins and the integrin-
associated thrombospondin receptor, CD47. Immuno-
ﬂuorescence of cells transfected with epitope-tagged
P2Y
 
2
 
Rs indicated that 
 
a
 
V
 
 integrins colocalized 10-fold
better with the wild-type P2Y
 
2
 
R than with a mutant
P2Y
 
2
 
R in which the RGD sequence was replaced with
RGE. Compared with the wild-type P2Y
 
2
 
R, the RGE
mutant required 1,000-fold higher agonist concentra-
tions to phosphorylate focal adhesion kinase, activate
extracellular signal–regulated kinases, and initiate the
 
PLC-dependent mobilization of intracellular Ca
 
2
 
1
 
. Fur-
thermore, an anti-
 
a
 
V
 
 integrin antibody partially inhib-
ited these signaling events mediated by the wild-type
P2Y
 
2
 
R. Pertussis toxin, an inhibitor of G
 
i/o
 
 proteins,
partially inhibited Ca
 
2
 
1
 
 mobilization mediated by the
wild-type P2Y
 
2
 
R, but not by the RGE mutant, suggest-
 
ing that the RGD sequence is required for P2Y
 
2
 
R-
mediated activation of G
 
o
 
, but not G
 
q
 
. Since CD47 has
been shown to associate directly with G
 
i/o
 
 family pro-
teins, these results suggest that interactions between
P2Y
 
2
 
Rs, integrins, and CD47 may be important for cou-
pling the P2Y
 
2
 
R to G
 
o
 
.
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Introduction
 
Cellular signaling by G protein–coupled receptors
(GPCRs)
 
1
 
 not only involves direct coupling to heterotri-
meric G proteins, but also involves the formation of larger
protein complexes that assist in transmitting an extracellu-
lar signal to an intracellular response. For example,
GPCRs activated by gamma-aminobutyric acid (GABA)
can form a heteromeric complex with other gamma-ami-
nobutyric acid receptors that is essential for activation of
inwardly rectifying potassium channels (Jones et al., 1998).
Also, several studies have proposed that GPCRs activate
mitogen-activated protein (MAP) kinases, such as an ex-
tracellular regulated kinase (ERK1/2), by using 
 
b
 
-arrestin
or tyrosine kinase receptors as scaffolding for GPCR-
induced Ras complex assembly (Pawson and Scott, 1997;
Luttrell et al., 1999). To add to the complexity, there ap-
pears to be a great deal of heterogeneity in the molecular
mechanisms a particular GPCR uses to activate MAP ki-
nases depending on the scaffolding proteins present in a
particular cell type (Della Rocca et al., 1999).
In this paper, we have explored protein complex forma-
tion between integrins and the P2Y
 
2
 
 nucleotide receptor
(P2Y
 
2
 
R), a G
 
o
 
- and G
 
q
 
-coupled receptor that is stimulated
by ATP or UTP and mediates activation of PLC-
 
b
 
 and
MAP kinases (Erb et al., 1994; Boarder et al., 1995). Se-
quence analysis and molecular modeling of mouse and hu-
man P2Y
 
2
 
R cDNAs predicted that the first extracellular
loop of this receptor contains the integrin-binding domain
RGD (Lustig et al., 1996; van Rhee et al., 1998). RGD has
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been shown to be the core recognition sequence for many
integrins, including 
 
a
 
V
 
b
 
3
 
, 
 
a
 
V
 
b
 
5
 
, 
 
a
 
V
 
b
 
11
 
, 
 
a
 
5
 
b
 
1
 
, and 
 
a
 
IIb
 
b
 
3
 
(Hynes, 1992), and is present in a variety of integrin
ligands, including collagen, fibronectin, and other extracel-
lular matrix proteins, blood-borne adhesive proteins, viral
coat proteins, bacterial membrane proteins, proteins from
the IgG superfamily, snake venom proteins, and other in-
tegrins (Clark and Brugge, 1995; Frenette and Wagner,
1996). Also, bioactive proteins containing an RGD se-
quence, such as the insulin-like binding protein 1, have
been shown to interact directly with integrins (Jones et al.,
1993). To address the possibility that the P2Y
 
2
 
R inter-
acts with a specific integrin, we used cell transfectants ex-
pressing recombinant wild-type (RGD) or RGE mutant
P2Y
 
2
 
Rs, as well as synthetic RGD- and RGE-containing
peptides modeled after the first extracellular loop of the
receptor. We also examined how the RGD to RGE muta-
tion affects P2Y
 
2
 
R-mediated signal transduction. The re-
sults of this study suggest that the RGD sequence of the
P2Y
 
2
 
R is responsible for forming a complex with the inte-
grins 
 
a
 
V
 
b
 
3
 
 and 
 
a
 
V
 
b
 
5
 
, and with CD47, a receptor for throm-
bospondin belonging to the IgG superfamily that is known
to couple directly to 
 
b
 
1
 
, 
 
b
 
2
 
, and 
 
b
 
3
 
 integrins and to hetero-
trimeric G proteins in the G
 
i/o
 
 family (Frazier et al., 1999).
 
Materials and Methods
 
Antibodies and Peptides
 
Anti–human 
 
a
 
5 
 
and 
 
a
 
V
 
b
 
5 
 
mAbs, anti–human 
 
a
 
5
 
b
 
1
 
 polyclonal antibody
(pAb), FITC-labeled goat anti–mouse F(ab)
 
2
 
 antibody, and human fi-
bronectin were purchased from GIBCO BRL. Anti–human 
 
a
 
V
 
 mAb was
purchased from Zymed Laboratories. Anti–human leukocyte antigen
class II mAb was purchased from Immunotech. The production of 7G2
(mouse anti–human 
 
b
 
3 
 
mAb) and B6H12 (mouse anti–human CD47
mAb) has been described previously (Gresham et al., 1989; Brown et al.,
1990). Anti-hemagglutinin (HA) pAb, antiphosphotyrosine mAb, anti–
human 
 
a
 
3 
 
mAb, and anti–mouse IgG conjugated to HRP were purchased
from Santa Cruz Biotechnology, Inc. Anti–mouse IgG conjugated to Cy5
and anti–rabbit IgG conjugated to Oregon green 488 were purchased from
Molecular Probes, and anti–focal adhesion kinase (FAK) mAb was pur-
chased from Upstate Biotechnology. Human vitronectin was purchased
from Calbiochem. RGDs and RGEs were purchased from Sigma-Aldrich.
The peptide corresponding to amino acids 93–110 of the human P2Y
 
2
 
R,
YARGDHWPFSTVLCKLVR (P2Y
 
2
93–110
 
), and the peptide YARGEH-
WPFSTVLCKLVR in which the aspartic acid was replaced with glutamic
acid (P2Y
 
2
93–110
 
[E
 
97
 
]) were synthesized at the Eppley Core Laboratory
(University of Nebraska Medical Center, Omaha, NE). P2Y
 
2
93–110
 
 and
P2Y
 
2
93–110
 
(E
 
97
 
) were synthesized on a peptide synthesizer (431A; Applied
Biosystems) using Fmoc chemistry and purified on a Waters Delta Prep
4000 system by reverse-phase HPLC with 0.1% trifluoroacetic acid in wa-
ter versus 0.1% trifluoroacetic acid in acetonitrile using two Delta-Pak
C18 40
 
3 
 
100 mm cartridges with 15 
 
m
 
m particle size and 300 Å pore size.
Matrix-assisted laser desorption ionization (time of flight) mass spectrom-
etry was used to verify the amino acid composition of P2Y
 
2
93–110
 
 and
P2Y
 
2
93–110
 
(E
 
97
 
).
 
Cell Culture and Transfection
 
Human K562 erythroleukemia cells (CCL 243; American Type Culture
Collection) were cultured in suspension in RPMI 1640 medium (GIBCO
BRL) containing 10% fetal bovine serum, 2 mM glutamine, 100 U/ml pen-
icillin, and 100 
 
m
 
g/ml streptomycin. Human 1321N1 astrocytoma cells
(Parr et al., 1994) were cultured in DME (GIBCO BRL) containing 5%
FBS, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin. Cells were main-
tained at 37
 
8
 
C in a humidified atmosphere of 5% CO
 
2
 
 and 95% air. The
retroviral vector, pLXSN, was used for stable expression of the various
P2Y
 
2
 
R constructs in 1321N1 cells as described previously (Erb et al.,
1995). In brief, the recombinant P2Y-pLXSN constructs were used to
 
transfect PA317 amphotrophic packaging cells for production of the viral
vectors. Then, 1321N1 cells were infected with the viral vectors and se-
lected for neomycin resistance with 1 mg/ml G418 (GIBCO BRL).
 
Immunofluorescent Staining and Visualization
 
Fluorescence-activated Cell Sorting. 
 
K562 cells (10
 
6
 
 cells/ml) were centri-
fuged (100 
 
g
 
 at 4
 
8
 
C) and the cell pellet was resuspended in 100 
 
m
 
l of HBSS
(GIBCO BRL) with or without antibodies to 
 
a
 
5
 
, 
 
a
 
V
 
b
 
5
 
, or 
 
b
 
3
 
 (0.2 mg/ml).
After a 30-min incubation at 4
 
8
 
C, the cells were washed twice with 1 ml of
PBS (GIBCO BRL) and incubated for 30 min at 4
 
8
 
C in 100 
 
m
 
l of HBSS
containing 1:100 dilution of FITC-conjugated antimurine IgG. The cells
were washed three times with 1 ml of PBS, fixed with 300 
 
m
 
l of 1% (wt/
vol) paraformaldehyde in PBS containing 50 
 
m
 
M CaCl
 
2
 
, and stored at 4
 
8
 
C
protected from light. The cells were then transferred to 12 
 
3
 
 75-mm tubes
and fluorescence intensity was determined using a flow cytometer (EPICS
753; Beckman Coulter).
 
Dual Immunofluorescence Labeling. 
 
1321N1 cells expressing HA-tagged
P2Y
 
2
 
R constructs were plated on glass coverslips and grown to 
 
z
 
40%
confluence. The cells were incubated for 1 h at 22
 
8
 
C with 1:100 dilution of
rabbit anti-HA pAb in DME containing 3% BSA, washed in PBS, and in-
cubated for 1 h at 22
 
8
 
C with 1:100 dilution of anti–rabbit IgG conjugated
to Cy5 in DME containing 3% BSA. The cells were then washed in PBS,
fixed in 1% formalin in PBS for 10 min, lysed with 0.5% Triton X-100 in
H
 
2
 
O for 1 min, and washed again in PBS. The fixed cells were incubated
for 1 h at 22
 
8C in PBS containing 3% BSA and 1:100 dilution of mouse
anti-aV mAb, washed in PBS, and incubated for 1 h at 228C in PBS con-
taining 3% BSA and 1:100 dilution of anti–mouse IgG conjugated to Ore-
gon green. The dual-labeled cells were washed in PBS, rinsed in H2O, and
mounted on glass slides in Prolong Antifade reagent (Molecular Probes).
Digital images of the dual-labeled cells were taken on a confocal micro-
scope (MRC600; Bio-Rad Laboratories), processed with CoMOS soft-
ware, and visualized with Adobe Photoshop® v5.5 in which red was as-
signed to Cy5 fluorescence and green was assigned to Oregon green
fluorescence. Yellow pixels, representing colocalization of P2Y2Rs and aV
integrins, were quantified in single cells from a Photoshop® histogram. In
brief, single cell images (1.64 mm/pixel magnification) were selected from
a flattened, 24-bit RGB mode document and copied to a new document in
CYMK mode where curves for cyan, magenta, and black, representing im-
age noise, were reduced to 0. Pixels within counts 1–50 of the resulting yel-
low histogram were recorded as the total number of yellow pixels per cell.
Ligand-coated Bead-binding Assay
Preparation of ligand-coated beads and analysis of their binding to cells
were performed as described (Lindberg et al., 1993), with modifications to
mask unreacted sites on the coated beads and to reduce nonspecific bead
binding. Ligand-coated beads were prepared by incubating 1.3-mm diame-
ter aldehyde-modified fluorescent latex beads (4 3 108/ml; Molecular
Probes) with 0.25 mM P2Y2
93–110, 0.25 mM P2Y2
93–110(E97), 0.04 mg/ml fi-
bronectin, 0.02 mg/ml vitronectin, or 0.04 mg/ml human serum albumin
(HSA) in 225 ml of PBS. After 1 h incubation at 378C, the beads were son-
icated for 10 s and added to 12.5 mg/ml HSA in 800 ml of PBS containing
0.1 M glycine to mask unreacted sites. After 30 min incubation at 378C,
the beads were centrifuged (2,000 g for 5 min) and resuspended in 1 ml of
HBSS supplemented with 10 mM Hepes, pH 7.4, 1% HSA, 4.2 mM
NaHCO3, 50 mg/ml gentamicin, and 1 mM MnCl2 (modified HBSS). The
peptide-coated beads were sonicated for 5 s immediately before use with
an Artek probe sonicator at the microtip limit setting. K562 cells (1.5 3
105) were preincubated in 70 ml of modified HBSS with various concentra-
tions of indicated peptide or antibody for 15 min at 228C, followed by the
addition of 1.7 3 107 ligand-coated beads. After 1 h incubation at 378C,
the number of beads bound to cells was determined by fluorescence mi-
croscopy (Lindberg et al., 1993). Binding was calculated as the adhesion
index (AI), defined as the number of beads bound per 100 cells.
Receptor Constructs
Incorporation of the HA Epitope into the P2Y2R. Wild-type human P2Y2R
cDNA was subcloned into the retrovirus expression vector pLXSN at the
EcoRI/BamHI sites of the multiple cloning site. The open reading frame
of the wild-type P2Y2R cDNA was modified to incorporate at the NH2
terminus of the expressed protein, the HA epitope (YPYDVPDYA) from
influenza virus, by using the PCR. The forward and reverse HA primers
were, respectively: 59-GATCGTGAATTCTGATGTATCCATATGAT-
GTTCCAGATTATGCTGCAGCAGACCTGGAACCCTGG-39 and 59-Erb et al. P2Y2R Interactions with aVb3 Integrins 493
GATCGTGGATCCCCTGACTGAGGTGCTATAGCCG-39. The PCR
solution contained primers (0.7 mM each), 10 ml of 103 Vent polymerase
buffer (New England Biolabs, Inc.), 100 ng of template DNA, 1 U Vent
(exo1) polymerase, and 20 ml of dNTP mixture (0.2 mM dATP, dCTP,
dTTP, and dGTP) in a final volume of 100 ml. The PCR parameters were:
968C for 1 min, 628C for 1 min, and 728C for 2.5 min for 25 cycles. After
verification of the PCR amplification products by agarose gel electro-
phoresis, the products were purified using a Promega PCR Wizard kit.
The purified PCR products and pLXSN DNA were digested overnight
with EcoRI and BamHI and ligated together, followed by transformation
of competent Escherichia coli and identification of positive clones. All
mutant DNAs were sequenced on both strands to ensure mutagenesis had
occurred as predicted using an ABI Prism automated sequencer (Per-
kinElmer) and fluorescence dideoxy-nucleotide technology.
Site-directed Mutagenesis of P2Y Receptor cDNA. A codon for glutamic
acid (E) was substituted for D116 and D121 of the turkey P2Y1R and D97 of
the human P2Y2R cDNAs by the PCR method described above, except
that the forward and reverse P2Y1R-E116 primers were, respectively: 59-
GCCTCCACCAAGTGCTCCCTG-39 and 59-CCTCTGCAGTTTGCA-
CATGACATCCCCGAAGATCCATTCGGTTTT-39. The forward and
reverse P2Y1E121R primers were, respectively: 59-GCCTCCACCAAGT-
GCTCCCTG-39 and 59-CCTCTGCAGTTTGCACATGACTTCCCC-
GAA-39. The 260-bp PCR products were excised from a 0.7% agarose gel,
cut with the restriction enzymes PstI and DraIII, and substituted for the
wild-type PstI/DraIII cDNA fragment in a P2Y1R-p bluescript construct.
The P2Y1R-E116 and P2Y1R-E121 cDNAs were subcloned into the BamHI
polylinker site of pLXSN for mammalian cell expression. This protocol
was also used to make the F119 to R119 mutation in the turkey P2Y1R
cDNA, in which the forward and reverse P2Y1R-R119 primers were, re-
spectively: 59-GCCTCCACCAAGTGCTCCCTG-39 and 59-CCTCTG-
CAGTTTGCACATGACATCCCCGCGGATCCAGT-39. The forward
and reverse P2Y2R-E97 primers were, respectively: 59-CGCCCGCGGC-
GAACACTGGCCC-39 and 59-AGACACCGGTGCACG-39. The 110-bp
PCR product was excised from a 0.7% agarose gel, cut with the restriction
enzymes SacII and AgeI, and substituted for the wild-type SacII/AgeI
cDNA fragment in the HA-tagged P2Y2R-pLXSN construct. The mutant
cDNA sequences were verified by using fluorescence dideoxy-nucleotide
sequencing, as described above.
Measurement of Cell Signaling Pathways
Calcium Assay. The intracellular free calcium concentration ([Ca21]i) was
measured by dual excitation spectrofluorometric analysis of cell suspen-
sions loaded with fura-2 (Sigma-Aldrich) as described previously (Lustig
et al., 1992) and assayed in Hepes-buffered saline (10 mM Hepes, pH 7.4,
130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM glucose).
Concentration–response data were analyzed with the Prism curve-fitting
program (GraphPAD).
IP Assay. To measure accumulation of IPs, 1321N1 cells expressing
P2Y2R were plated in 12-well dishes and incubated in the presence or ab-
sence of specified antibodies for 24 h in 0.7 ml serum-free and inositol-free
DME containing 2 mCi of [3H]inositol (20 Ci/mmol). The cells were
washed three times and incubated for 30 min at 378C in 1 ml of LiCl solu-
tion (15 mM glucose, 25 mM Hepes, 110 mM NaCl, 5 mM KCl, 1.8 mM
CaCl2, 0.9 mM MgCl2, and 30 mM LiCl) followed by stimulation with 0.1
mM UTP for 10 min. The reactions were stopped by aspiration and cell ex-
tracts were obtained by addition of 0.3 ml of ice-cold 10% perchloric acid
for 15 min. The extracts were neutralized with 0.6 ml of 2 M NaOH and
225 mM Hepes. The IPs in the neutralized extracts were separated from
inositol and glycerophosphoinositol on Dowex columns as described pre-
viously (Berridge et al., 1983). Radioactivity in the IP fraction was deter-
mined by liquid scintillation spectrometry using Ecolume scintillation
fluid.
FAK and ERK1/2 Phosphorylation. 1321N1 cells expressing P2Y2R con-
structs were grown to 80% confluence in six-well plates and incubated at
378C in medium without serum for 24 h before the experiment. After stim-
ulation, the cells were washed with ice-cold PBS and lysed with 250 ml of
lysis buffer (25 mM Tris-HCl, pH 7.4, 25 mM NaCl, 1 mM Na3VO4, 10
mM NaF, 10 mM Na4(P2O7), 25 mM b-glycerophosphate, 25 mM p-nitro-
phenylphosphate, 0.5 mM EGTA, 0.5% Triton X-100, 1 mM PMSF, 10
mg/ml aprotinin, 10 mg/ml leupeptin, 10 nM okadaic acid). The extracts
were centrifuged (8,200 g for 10 min at 48C) to remove insoluble material,
solubilized in 100 ml of 23 Laemmli sample buffer (120 mM Tris-HCl, pH
6.8, 2% SDS, 10% sucrose, 1 mM EDTA, 50 mM dithiothreitol, 0.003%
bromophenol blue), heated for 3 min at 968C, subjected to 7.5% SDS-
PAGE, and transferred to nitrocellulose membranes for protein immuno-
blotting. Immunoblotting of tyrosine phosphorylated FAK was performed
by using 1:1,500 dilution of rabbit antiphospho FAK Tyr397 IgG (Upstate
Biotechnology) as the primary antibody and 1:2,000 dilution of HRP-con-
jugated anti–rabbit IgG as the secondary antibody. Immunoblotting of
phosphorylated ERK1/2 was performed by using 1:1,000 dilution of
mouse antiphospho p42/p44 MAP kinase IgG (Cell Signaling) as the pri-
mary antibody and 1:2,000 dilution of HRP-conjugated anti–mouse IgG as
the secondary antibody. Chemiluminescence in the blots was visualized on
autoradiographic film with the LumiGlo chemiluminescence system (New
England BioLabs, Inc.) and was quantitated by using a GS-525 molecular
imager and MultiAnalyst software (Bio-Rad Laboratories). For normal-
ization of the signal, the membranes were stripped of antibodies by a 30
min incubation at 608C in stripping buffer (62.5 mM Tris-HCl, pH 6.7, 100
mM 2-mercaptoethanol, and 2% SDS), washed with TTBS, and reprobed
with 1:1,000 dilution of anti-FAK or anti-p42/p44 MAP kinase as the pri-
mary antibodies, which bind to FAK or ERK1/2 independent of their
phosphorylation state.
Alternatively, tyrosine phosphorylation of FAK was analyzed by im-
munoprecipitation of FAK as described by the antibody manufacturer
(Upstate Biotechnology) followed by immunoblotting of the precipitated
protein with 1:1,500 dilution of mouse antiphosphotyrosine monoclonal
IgG as the primary antibody and 1:1,500 dilution of HRP-conjugated anti–
mouse IgG as the secondary antibody.
Results
P2Y2
93–110 Interacts Specifically with aVb3/b5 
Integrins and CD47
To investigate whether the RGD domain of the P2Y2R fa-
cilitates binding to a specific integrin, we coupled a pep-
tide derived from the human P2Y2R, YARGDHW-
PFSTVLCKLVR (P2Y2
93–110) to fluorescent beads and
assessed the ability of the peptide-coated beads to adhere
to human K562 erythroleukemia cells. Integrin receptor
expression in K562 cells has been reported to be limited to
the fibronectin-binding integrin a5b1 (Hemler et al., 1987),
but expression of other integrin subunits (a2, a3, aV, and
b3) can be induced by treatment of the cells with the pro-
tein kinase activator phorbol dibutyrate (PDBu; Burger et
al., 1992; Jarvinen et al., 1993). To examine cell surface ex-
pression of integrin receptors, K562 cells were incubated
with antibodies to a5, aVb5, or b3 and subjected to fluores-
cence-activated cell sorting. We found that 88, 63, and
74% of the K562 cells were positively stained by antibod-
ies to a5, aVb5, and b3, respectively, and that an overnight
treatment of K562 cells with 100 nM PDBu did not in-
crease the fluorescence intensity or percentage of cells
stained by these antiintegrin antibodies (not shown). This
indicates that the K562 cell line used in this study ex-
presses vitronectin-binding integrins (aVb3 and aVb5) and
that cell surface expression of these integrins does not re-
quire PDBu-mediated stimulation of protein kinase C.
Results of the peptide-binding studies indicated that
P2Y2
93–110-coated beads bound to K562 cells with an AI of
580 6 71 (mean 6 SEM, n 5 6), whereas fibronectin- and
vitronectin-coated beads exhibited AI values of 318 6 14
(n 5 3) and 300 6 28 (n 5 3), respectively (Fig. 1 A). The
AI for nonspecific binding, determined with human serum
albumin–coated beads, was 46 6 10 (n 5 3), and the AI
for beads coated with an RGE mutant P2Y2 peptide,
YARGEHWPFSTVLCKLVR (P2Y2
93–110[E97]), was 70 6
18 (n 5 3). Previous studies indicated that the RGE se-
quence has a low affinity for integrins (Hautanen et al.,
1989). Soluble P2Y2
93–110 inhibited K562 cell binding of
P2Y2
93–110- and vitronectin-coated beads (IC50 equals 30 6The Journal of Cell Biology, Volume 153, 2001 494
15 mM and 105 6 35 mM, respectively), but not fibronec-
tin-coated beads, suggesting that this peptide interacts
with an integrin receptor that binds vitronectin.
The specificity of binding between K562 cells and
P2Y2
93–110-coated beads was determined by preincubating
the cells with antibodies raised against specific integrins or
integrin-associated proteins. P2Y2
93–110-coated bead bind-
ing to K562 cells was inhibited by mAbs to b3, aVb5, or
CD47, but not by antibodies to the a5b1 integrin (Fig. 1 B).
These results suggest that the RGD peptide corresponding
to the first extracellular loop of the P2Y2 receptor binds
specifically to aVb3/b5 integrins, but not to the a5b1 inte-
grin expressed in K562 cells. The finding that anti-CD47
antibodies could also inhibit binding of P2Y2
93–110-coated
beads to K562 cells supports the involvement of an aVb3
integrin, since CD47 was shown previously to associate
with b3 integrins and regulate vitronectin binding to the
aVb3 integrin (Lindberg et al., 1993).
RGD-dependent Colocalization of the P2Y2R 
with aV Integrins
To determine whether the full-length P2Y2R interacts
with  aVb3/b5 integrins, we expressed HA-tagged wild-type
or RGE mutant P2Y2Rs in human 1321N1 astrocytoma
cells and used immunofluorescence to analyze the distri-
bution of these receptors relative to the aV integrin sub-
unit. Confocal microscopy of dual-labeled 1321N1 cell
transfectants showed that endogenously expressed aV ex-
hibited z10-fold higher levels of colocalization with the
wild-type P2Y2R than with the RGE mutant P2Y2R (Fig.
2). Furthermore, colocalization of aV and the wild-type
P2Y2R occurred whether or not the cells were treated with
100 mM UTP (Fig. 2), indicating that association of these
proteins is not dependent on P2Y2R activation.
The RGD Domain of the P2Y2R Regulates Go-mediated 
Ca21 Mobilization and Other Signaling Events
Functional studies indicated that the RGE mutant P2Y2R
required z1,000-fold higher concentrations of the agonists
ATP or UTP than the wild-type P2Y2R to stimulate PLC-
dependent mobilization of intracellular Ca21 in human
1321N1 cell transfectants (Fig. 3 A). The difference in ago-
nist potencies between the wild-type and RGE mutant
P2Y2Rs in the cell transfectants was not due to differences
in the level of cell surface receptor expression, since fluo-
rescence-activated cell sorting of intact cells labeled with
anti-HA antibodies confirmed that both HA-tagged wild-
type and RGE mutant P2Y2Rs had similar expression lev-
els (not shown). It is also unlikely that the RGE mutation
in the first extracellular loop of the P2Y2R affects ligand
binding since receptor modeling and mutagenesis studies
have indicated that the ligand-binding determinants for
both the P2Y1 and P2Y2 receptor subtypes are located
within the third, sixth, and seventh transmembrane do-
mains (Erb et al., 1995; van Rhee et al., 1998). However, to
address the possibility that the D to E point mutation in
the P2Y2R was affecting ligand binding, we analyzed the
effect of similar point mutations in the structurally related
P2Y1 receptor. The ADP-selective P2Y1R does not ex-
press the RGD integrin-binding motif, but does contain an
aspartic acid residue (KTD116) in almost the same position
as the aspartic acid residue in the RGD97 sequence of the
P2Y2R (Table I). To investigate the ability of D116 in the
P2Y1R to influence agonist-induced Ca21 mobilization, we
expressed in 1321N1 cells a P2Y1R containing a KTD116 to
KTE mutation. Unlike the RGE mutant P2Y2R, the KTE
mutant P2Y1R exhibited the same agonist potency as the
wild-type P2Y1R (Table I). Likewise, mutation of another
aspartic acid residue in the first extracellular loop of the
P2Y1R (FGD121 to FGE) had no effect on agonist potency
(Table I). Interestingly, when we mutated FGD to RGD
in the P2Y1R, it then required .30-fold higher concentra-
tions of ADP to stimulate Ca21 mobilization compared
with the wild-type P2Y1R (Table I). Although these re-
sults do not prove whether or not ligand binding to the
Figure 1. P2Y2 peptide-coated bead binding to K562 cells is in-
hibited by a soluble RGD peptide and antibodies to aVb3/b5 inte-
grins and CD47. (A) Latex beads were coated with the indicated
peptide or protein and incubated with K562 cells suspended in
HBSS for 1 h at 378C in the presence or absence of preincubation
peptide. The amount of bead binding to K562 cells was deter-
mined and the AI values were calculated. The data are the
mean  6 SEM (n 5 3–6). (B) K562 cells were preincubated for 15
min in HBSS alone or in the presence of antiintegrin, control an-
ticlass II HLA, or anti-CD47 antibodies. P2Y2
93–110 peptide-
coated latex beads were added and the incubation was continued
for 1 h at 378C. The AI values were calculated and the percentage
of bead binding to K562 cells compared with the control (HBSS
alone) is shown. The data are the mean 6 SEM (n 5 3).Erb et al. P2Y2R Interactions with aVb3 Integrins 495
P2Y2R is affected by the RGD97 to RGE mutation, they
do, by comparison, suggest that D to E mutations in the
first extracellular loop of P2YRs are not important for re-
ceptor activity but, rather, it is expression of the RGD in-
tegrin-binding domain that influences receptor activity.
The Gi/o inhibitor pertussis toxin caused a 30% inhibi-
tion of Ca21 mobilization mediated by the wild-type
P2Y2R expressed in 1321N1 cells, whereas Ca21 mobiliza-
tion mediated by the RGE mutant receptor was insensi-
tive to pertussis toxin treatment (Fig. 3 B). This supports
other studies indicating that the P2Y2R activates both Go-
and Gq-mediated calcium signaling (Erb et al., 1994), and
further indicates that substitution of the RGD integrin-
binding domain with RGE preferentially affects Go-medi-
ated calcium signaling.
Previous studies indicated that the P2Y2R mediates ty-
rosine phosphorylation of FAK (Soltoff et al., 1998a), a
protein known to be associated with integrins, focal adhe-
sions, and cytoskeletal proteins (Clark and Brugge, 1995).
Fig. 4 A shows that FAK phosphorylation by the RGE
mutant P2Y2R requires z1,000-fold higher concentrations
of the agonist UTP, as compared with the wild-type
P2Y2R. FAK phosphorylation mediated by the wild-
type  and RGE mutant P2Y2Rs was dependent on intracel-
lular Ca21 mobilization, since preincubation with the
calcium chelating agent 1,2-bis(2-aminophenoxy)ethane-
Figure 2. Colocalization of P2Y2Rs with aV integrins. Human 1321N1 cells expressing HA-tagged wild-type or RGE mutant P2Y2Rs
were incubated at 378C with or without 1 mM UTP for 5 min. The HA-tagged receptors were detected by confocal microscopy and im-
munofluorescence with the dye Cy5 (shown in red) and aV integrins in the same cells were detected by immunofluorescence with the
dye Oregon green (shown in green). The combined fluorescence, indicative of colocalization, is shown in yellow. The data are both rep-
resentative and the mean 6 SEM (n 5 6).The Journal of Cell Biology, Volume 153, 2001 496
N,N,N9,N9-tetraacetic acid (BAPTA) inhibited UTP-
induced FAK phosphorylation in 1321N1 cell transfectants
(Fig. 4 B). These results are consistent with the conclusion
that the RGD sequence of the P2Y2R promotes efficient ac-
tivation of the calcium-dependent signaling pathway.
P2Y2R activation in 1321N1 cells also leads to phos-
phorylation of the MAP kinases, ERK1/2. Similar to results
from experiments on calcium mobilization and calcium-
dependent FAK phosphorylation (Figs. 3 and 4), ERK1/2
phosphorylation by the RGE mutant P2Y2R requires
z1,000-fold higher concentrations of UTP, as compared
with the wild-type P2Y2R (Fig. 5 A). Depending on the
cell type, ERK1/2 phosphorylation by the P2Y2R has been
found to occur by the calcium-independent activation of
protein kinase Cd and phospholipase D (Neary et al.,
1999) and/or by the calcium-dependent transactivation of
the EGF receptor (Soltoff, 1998b). In 1321N1 cell trans-
fectants, we found that ERK1/2 phosphorylation by the
wild-type P2Y2R was partially inhibited by the calcium
chelator BAPTA, whereas ERK1/2 phosphorylation by
the RGE mutant was not affected by BAPTA treatment
(Fig. 5 B). Thus, it appears that activation of ERK1/2 by
the P2Y2R in 1321N1 cells involves both calcium-depen-
dent and -independent events and that the RGD sequence
of the P2Y2R primarily assists in activating the calcium-
dependent ERK1/2 signaling pathway.
P2Y2R-mediated Signaling Is Inhibited by Anti-aV 
Antibodies and by RGDS
We investigated whether an antibody raised against the
aV integrin subunit could interfere with UTP-stimulated
P2Y2R signal transduction. To analyze the affect of this an-
tibody on the P2Y2R calcium signaling pathway, we mea-
sured IP formation since inositol 1,4,5-trisphosphate (IP3)
is the second messenger for intracellular calcium mobiliza-
tion (Weisman et al., 1998). The results indicated that
overnight treatment with anti-aV antibody partially inhib-
ited IP formation induced by UTP (Fig. 6 A), consistent
with the decreased calcium response seen for RGE mutant
receptors as compared with wild-type P2Y2R (Fig. 3). Sim-
ilarly, phosphorylation of FAK, a calcium-dependent re-
sponse (Fig. 4 B), was partially inhibited by anti-aV anti-
body (Fig. 6 B). ERK1/2 phosphorylation was inhibited by
Table I. Sequence Alignment and Effect of Point Mutations on Functional Activity of the P2Y1R and P2Y2R
Receptor construct EC50 (for Ca21 mobilization)
P2Y1R (wild-type) 0.06 6 0.01 (mM ADP)
P2Y1R (D116 ° E 0.06 6 0.01
P2Y1R (D121 ° E) 0.08 6 0.01
P2Y1R (F119 ° R) 2.02 6 0.27
P2Y2R (wild-type) 0.85 6 0.13 (mM ATP)
P2Y2R (D97 ° E) 785 6 125
(Top) Sequence alignment of human P2Y1R and P2Y2R between the second and third transmembrane regions. Amino acid residues subjected to point mutation are underlined.
(Bottom) EC50 values for activation of calcium mobilization in wild-type and mutant P2Y1Rs and P2Y2Rs expressed in 1321N1 cells. The data are the mean 6 SEM (n = 3).
Figure 3. Calcium mobilization mediated by wild-type and RGE
mutant P2Y2Rs. (A) Human 1321N1 cells expressing either wild-
type (open symbols) or RGE mutant (filled symbols) P2Y2Rs were
assayed for receptor activity by quantitating changes in the con-
centration of cytoplasmic free calcium ([Ca21]i) in response to the
indicated concentration of ATP (squares) or UTP (circles). Data
are expressed as a percentage of the maximum increase in [Ca21]i
elicited by the most effective ligand for each receptor construct
and represent the mean 6 SEM (n 5 3). (B) 1321N1 transfectants
were treated overnight with or without 200 ng/ml Bordetella per-
tussis toxin (PTX). The maximum change in [Ca21]i in response
to 1 mM UTP for the wild-type P2Y2R transfectants or 100 mM
UTP for the RGE mutant P2Y2R transfectants is shown as the
mean 6 SEM (n 5 3) from one experiment and is representative
of three separate experiments. The resting [Ca21]i was z130 nM
for each condition.Erb et al. P2Y2R Interactions with aVb3 Integrins 497
anti-aV antibody to a lesser extent than FAK phosphoryla-
tion or IP formation (Fig. 6 C), consistent with the pres-
ence of both calcium-dependent and calcium-independent
pathways for ERK1/2 phosphorylation (Fig. 5 B). Anti-a3
integrin antibody had no effect on the ability of the P2Y2R
to stimulate any of these signaling events (Fig. 6, A–C).
These findings suggest that interaction of aV integrin with
the P2Y2R is important for optimum P2Y2R activation.
Previous studies have indicated that overnight treat-
ment with the tetrapeptide RGDS, which inhibits integrin
dimerization and disrupts the formation of focal adhe-
sions, can also inhibit GPCR-mediated ERK1/2 activation
and FAK phosphorylation in certain cell types (Della
Rocca et al., 1999). We tested whether RGDS could simi-
larly influence FAK and ERK1/2 phosphorylation medi-
ated by the P2Y2R in 1321N1 cell transfectants. The
results indicated that overnight treatment with RGDS in-
hibited FAK and ERK1/2 phosphorylation, whereas the
control peptide, RGES, had no effect on the ability of the
P2Y2R to induce phosphorylation of these kinases (Fig. 7
A). P2Y2R-mediated Ca21 mobilization and IP formation
were not inhibited by overnight treatment with RGDS,
and shorter incubation periods with RGDS did not cause
inhibition of FAK or ERK1/2 phosphorylation (not
shown). However, a 2-h incubation with RGDS could in-
hibit P2Y2R-mediated FAK phosphorylation (Fig. 7 B),
but only if the P2Y2Rs were subjected to agonist-induced
sequestration (Garrad et al., 1998), in which the peptide
was added during the time period when the internalized
receptors were being recycled to the plasma membrane.
Figure 4. FAK phosphorylation mediated by the wild-type and
RGE mutant P2Y2Rs. Human 1321N1 cells expressing either
wild-type or RGE mutant P2Y2Rs were stimulated with (A) the
indicated concentration of UTP for 5 min at 378C or with (B) 1
mM UTP after a 30 min preincubation with buffer or 10 mM
BAPTA-AM. The cells were lysed in RIPA buffer and FAK was
immunoprecipitated from the lysate. Phosphorylation of FAK
was detected by Western blot analysis with an antiphosphoty-
rosine antibody. The data are representative of results from three
to six experiments.
Figure 5. MAP kinase activation mediated by the
wild-type and RGE mutant P2Y2Rs. Human
1321N1 cells expressing either wild-type or RGE
mutant P2Y2Rs were stimulated with (A) the indi-
cated concentration of UTP for 5 min at 378C or
with (B) 100 mM UTP after a 30 min preincubation
with buffer or 10 mM BAPTA-AM. MAP kinase ac-
tivation (ERK1 and ERK2 phosphorylation) was
detected by Western blot analysis with an antiphos-
pho ERK1/2 antibody as described in Materials and
Methods. The data are representative of results
from four to six experiments.The Journal of Cell Biology, Volume 153, 2001 498
Thus, the RGDS peptide is less effective as a modulator of
P2Y2R activity than anti-aV antibody.
Discussion
The results of this study suggest that an integrin-binding
domain (RGD) in the P2Y2R allows this receptor to asso-
ciate with aVb3/b5 integrins and the integrin-associated
thrombospondin receptor, CD47. Furthermore, mutation
of the RGD sequence to RGE in the P2Y2R or addition of
an anti-aV integrin antibody was found to inhibit P2Y2R
signal transduction (i.e., IP formation and phosphorylation
of FAK and ERK1/2). This suggests that interaction be-
tween P2Y2Rs and integrins either shifts the P2Y2R into a
high affinity state and/or allows efficient coupling of this
receptor to its intracellular signaling proteins. Currently,
there is no reliable assay for measuring ligand binding to
the P2Y2R, making it difficult to distinguish between these
Figure 6. Effect of antiintegrin antibodies on IP formation and FAK and ERK1/2 phosphorylation by the P2Y2R. Human 1321N1 cells
expressing wild-type P2Y2Rs were incubated for 24 h with or without 100 mg/ml of the indicated antibody. The cells were then stimu-
lated with 1 mM UTP for 10 min (A), 1 mM UTP for 5 min (B), or 10 nM UTP for 5 min (C). For A, generation of IP is expressed as the
percentage of maximum stimulation with UTP after background subtraction (backgrounds for control, a3-treated, and aV-treated sam-
ples were 18,462 6 1,090, 15,670 6 1,000, and 30,450 6 3,650 dpm, respectively). For B, FAK phosphorylation was assayed by Western
blot analysis with antiphospho FAK antibody as described in Materials and Methods. For C, ERK1/2 phosphorylation was assayed as
described in the legend to Fig. 5. The data for A are the mean 6 SEM (n 5 3). The data for B and C are both representative (bottom)
and the mean 6 SEM (n 5 3–5) (top).
Figure 7. Effect of RGDS and RGES peptides
on FAK and ERK1/2 phosphorylation by the
P2Y2R. Human 1321N1 cells expressing wild-
type P2Y2Rs were (A) incubated for 18 h with
100 mM of the indicated peptide or (B) treated
with 100 mM UTP for 10 min to induce internal-
ization of the P2Y2Rs, rinsed, and incubated for
2 h with 100 mM of the indicated peptide during
the time period when internalized P2Y2Rs are
being recycled to the plasma membrane (Garrad
et al., 1998). The cells were then stimulated with
1 mM UTP (for FAK experiments) or 10 nM
UTP (for ERK1/2 experiments) for 5 min at
378C. Phosphorylation of FAK and ERK1/2
were assayed as described in the legends to Figs.
4 and 5, respectively. The data are representative
of results from three to five experiments.Erb et al. P2Y2R Interactions with aVb3 Integrins 499
two possibilities. However, there is evidence that the latter
is affected. We found that the Gi/o inhibitor, pertussis
toxin, partially inhibited Ca21 signaling by the wild-type
P2Y2R, but not by the RGE mutant receptor. Since CD47
has been found to form a complex with integrins and pro-
teins in the Gi/o family (Frazier et al., 1999), these data sug-
gest that the P2Y2R requires integrin–CD47 interactions
to access Go.
Activation of CD47 has been shown to shift several inte-
grins into a high affinity state. For example, the CD47 ago-
nist 4N1K stimulates platelet spreading on a fibrino-
gen-coated surface and causes platelet aggregation by
activating the integrin aIIbb3 (Chung et al., 1997). In mela-
noma cells, activation of CD47 stimulates aVb3 integrin-
dependent cell spreading on a vitronectin-coated surface
(Gao et al., 1996). And in vascular smooth muscle cells, ac-
tivation of CD47 inhibits adenylate cyclase and ERK1/2
activity which stimulates a2b1 integrin-dependent chemo-
tactic migration toward soluble collagen (Wang et al.,
1999). In turn, there is evidence that integrin activation
can transactivate CD47. In melanoma cells, activation of
the aVb3 integrin with peptides derived from type IV col-
lagen causes Ca21 mobilization and chemotaxis, both of
which require CD47 (Shahan et al., 2000). Whether the
P2Y2R can also influence integrin or CD47 activity re-
mains to be seen. Nonetheless, the results presented here
suggest that signaling by the P2Y2R may depend on inter-
action with aVb3/b5 integrins and CD47 and support the
idea that functional diversity among members of the
GPCR superfamily is provided by differential linkage to
scaffolding proteins involved in the formation of a protein-
signaling complex (Montell, 1998).
The presence of an RGD sequence in an extracellular
domain of a GPCR is rare, occurring only in the first extra-
cellular loop of several species homologues of the P2Y2Rs
and P2Y6Rs and the third extracellular loop of the H2 his-
tamine receptor (GPCR database: http://www.gpcr.org).
In contrast to the human and murine P2Y2Rs, the rat ho-
mologue contains a QGD instead of an RGD sequence
(Rice et al., 1995). However, this change in the arginine
position of the RGD integrin-binding domain is consid-
ered to be a conservative substitution that maintains inte-
grin binding (Gresham et al., 1992).
Although the potential for a GPCR to physically inter-
act with an integrin has not been explored previously,
there is precedence for interactions between integrins and
other types of receptors containing an RGD sequence. For
example, the urokinase-type plasminogen-activated recep-
tor has been found to coimmunoprecipitate with the aMb2
integrin (Wei et al., 1996). Also, activated PDGFb recep-
tors and insulin receptors have been found to coimmuno-
precipitate with aVb3 integrins (Schneller and Ruoslahti,
1997), and the synergistic actions of aVb3 and the PDGF
receptor increase endothelial cell migration (Woodard et
al., 1998). Attempts to coimmunoprecipitate the HA-
tagged P2Y2R with the aV integrin thus far have been un-
successful. Studies that have successfully coimmunopre-
cipitated GPCRs and other proteins have found that (a)
covalent crosslinking of the proteins is necessary because
of the harsh conditions required to solubilize GPCRs and
(b) overexpression of both proteins is necessary for West-
ern blot detection (Luttrell et al., 1999). Therefore, we are
currently developing these techniques for coimmunopre-
cipition of proteins with P2Y2Rs. In this study, we have
shown by immunofluorescence microscopy that the HA-
tagged P2Y2R and the aV integrin colocalize in the plasma
membrane of 1321N1 astrocytoma cells and that the ex-
tent of colocalization between these proteins is z10-fold
greater than the level of colocalization between aV and the
RGE mutant receptor (Fig. 2). Although these data are
suggestive of a direct interaction between an integrin and
the RGD sequence of the P2Y2R, it is possible that the in-
teraction observed by microscopy reflects a transient, low-
affinity interaction or an interaction with the detergent in-
soluble actin cytoskeleton. If this is the case, it will require
more sophisticated techniques to demonstrate this interac-
tion by coimmunoprecipitation. Whatever the nature of
this RGD-dependent interaction, our data strongly sug-
gest that it is directly relevant to the regulation of P2Y2R-
mediated signal transduction.
The aVb3 integrin is expressed in vascular endothelial
cells and has been shown to play a vital role in angiogene-
sis, the de novo growth of blood vessels, a process essential
to the growth of solid tumors that has become an impor-
tant target in cancer therapy (Brooks et al., 1994a,b). The
P2Y2R is also expressed in vascular endothelial cells,
where it has been recognized for its antithrombotic and va-
sodilatory properties (Pearson et al., 1983; Boarder et al.,
1995). Activation of the P2Y2R has been shown to increase
prostacyclin and nitric oxide release from endothelial cells
(Lustig et al., 1992; Weisman et al., 1998), surfactant phos-
pholipid secretion from alveolar type II cells (Rice et al.,
1995), and inducible nitric oxide synthase expression in
macrophages (Denlinger et al., 1996). In addition to these
cells, the P2Y2R is expressed in kidney, liver, spleen, heart,
brain, and placental tissue (Lustig et al., 1993; Parr et al.,
1994). Recent studies have indicated that the P2Y2R is up-
regulated in activated thymocytes as an immediate early
gene response (Koshiba et al., 1997) and in epithelial cells
in response to ligation of the salivary gland duct (Turner et
al., 1998), whereas it is down-regulated during differentia-
tion of human myeloid leukocytes (Martin et al., 1997).
Also, activation of the P2Y2R in human umbilical vein en-
dothelial cells has been found to induce a transient, 10-fold
increase in av integrin expression that is inhibited by the
protein kinase C inhibitor GF109238 (Erb, L., C. Clamp,
and G.A. Weisman. 1998. International Society for Heart
Research–XVI World Congress. J. Mol. Cell. Cardiol. 30:
499). In endothelial cell cultures, P2Y2R expression is
readily apparent (Pearson et al., 1983; Lustig et al., 1992),
although it is more difficult to detect in mature blood ves-
sels (B. Krugh, unpublished observation). One hypothesis
is that the level of P2Y2R expression increases in response
to tissue damage or to cell perturbations associated with
culture procedures. If this hypothesis holds with endothe-
lial cell damage in vivo, the up-regulation of P2Y2Rs, like
aVb3, may occur under conditions that promote angiogene-
sis or atherosclerosis. Considering the wide-spread distri-
bution of P2Y2Rs, it seems likely that interactions between
P2Y2Rs and integrins, such as aVb3, could have a range of
physiological consequences yet to be delineated.
Here we have presented data suggesting that P2Y2Rs,
aVb3/b5 integrins, and CD47 interact within the same cell.
Is it also possible for these receptors to interact intercellu-The Journal of Cell Biology, Volume 153, 2001 500
larly and affect cell–cell adhesion? Several studies have in-
dicated that extracellular ATP and UTP can stimulate
cell–cell adhesion, although the molecular/biochemical ba-
sis for this interaction has not been identified. For exam-
ple, ATP and UTP have been shown to stimulate cell ad-
hesion in a monocyte/macrophage lineage (Ventura and
Thomopoulos, 1995) and enhance neutrophil adherence to
endothelial cell monolayers (Parker et al., 1996). Antibod-
ies to P-selectin, ICAM-1, and the b2 integrin subunit did
not prevent ATP-induced intercellular adherence between
neutrophils and endothelial cells (Parker et al., 1996), al-
though the contribution of aVb3/b5 integrins was not ex-
plored. The aVb3 integrin on monocytes mediates their ad-
herence to endothelial and epithelial cells (Beekhuizen
and Van Furth, 1993; Murphy et al., 1994), an early event
in the acute inflammatory response. Also, aVb3 and CD47
play a role in transendothelial monocyte and neutrophil
migration (Lindberg et al., 1996; Weerasinghe et al., 1998),
although a role for the P2Y2R as a counter-receptor for
aVb3 or CD47 has not been assessed. Studies by our group
have found that activated polymorphonuclear cells bind
more readily to K562 cells transfected with human P2Y2R
cDNA than to untransfected or vector-transfected K562
cells (H. Gresham, unpublished observation). Therefore,
cell–cell interactions between P2Y2Rs, aVb3/b5 integrins,
and CD47 are likely to have physiological consequences
and should be further investigated. Since peptides mod-
eled after the first extracellular loop of the P2Y2R bind se-
lectively to aVb3/b5 integrins and CD47 (Fig. 1 B), the po-
tential for P2Y2R-derived peptides to inhibit intercellular
interactions between these receptors also should be inves-
tigated. Such inhibitors of aVb3 integrin, CD47, and
P2Y2R interactions could prove useful as pharmacothera-
peutic agents in the treatment of atherosclerosis, diabetes,
cancer and inflammation.
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